131 related articles for article (PubMed ID: 35119175)
41. [Successful Hematopoietic Cell Transplantation Following Azacitidine Treatment in an Acute Myeloid Leukemia Patient with t(3;3)(q21;q26.2) Translocation and Marked Thrombocythemia].
Yoshida M; Kuroda H; Shimoyama S; Usami M; Yamada M; Fujii S; Maeda M; Fujita M; Kanari Y; Sato M; Jomen W; Iyama S; Kato J
Gan To Kagaku Ryoho; 2015 Aug; 42(8):1013-7. PubMed ID: 26321721
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of two chronic myelomonocytic leukemia patients with Decitabine].
Wang L; Wang HX; Zhao J
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):497. PubMed ID: 22213878
[No Abstract] [Full Text] [Related]
43. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?
Alessandrino EP; Della Porta MG; Pascutto C; Bacigalupo A; Rambaldi A
J Clin Oncol; 2013 Jul; 31(21):2761-2. PubMed ID: 23775971
[No Abstract] [Full Text] [Related]
44. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
[No Abstract] [Full Text] [Related]
45. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.
Craddock C; Jilani N; Siddique S; Yap C; Khan J; Nagra S; Ward J; Ferguson P; Hazlewood P; Buka R; Vyas P; Goodyear O; Tholouli E; Crawley C; Russell N; Byrne J; Malladi R; Snowden J; Dennis M
Biol Blood Marrow Transplant; 2016 Feb; 22(2):385-390. PubMed ID: 26363443
[TBL] [Abstract][Full Text] [Related]
46. Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients.
Leoncini PP; Vitullo P; Di Florio F; Tocco V; Cefalo MG; Pitisci A; Girardi K; Niemeyer C; Locatelli F; Bertaina A
Br J Haematol; 2018 Sep; 182(6):909-912. PubMed ID: 28771681
[No Abstract] [Full Text] [Related]
47. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
48. Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine.
Infante MS; Muñoz C; Heras C; Foncillas MA; González I; Lucea I; Echavarria E; Aramendi T; Hernández JA
Eur J Dermatol; 2015; 25(6):622-3. PubMed ID: 26552844
[No Abstract] [Full Text] [Related]
49. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Sekeres MA; Watts J; Radinoff A; Sangerman MA; Cerrano M; Lopez PF; Zeidner JF; Campelo MD; Graux C; Liesveld J; Selleslag D; Tzvetkov N; Fram RJ; Zhao D; Bell J; Friedlander S; Faller DV; Adès L
Leukemia; 2021 Jul; 35(7):2119-2124. PubMed ID: 33483617
[No Abstract] [Full Text] [Related]
50. [Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report].
Manabe M; Okita J; Takakuwa T; Harada N; Aoyama Y; Kumura T; Ohta T; Furukawa Y; Mugitani A
Gan To Kagaku Ryoho; 2014 Jun; 41(6):781-4. PubMed ID: 25129095
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B
J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646
[TBL] [Abstract][Full Text] [Related]
52. Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.
Jennane S; El Haddad M; Mahtat EM; Doghmi K; Mikdame M
Ann Biol Clin (Paris); 2017 Dec; 75(6):713-714. PubMed ID: 29043987
[No Abstract] [Full Text] [Related]
53. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
[No Abstract] [Full Text] [Related]
54. Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.
Della Porta MG; Alessandrino EP
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1260-1. PubMed ID: 25020100
[No Abstract] [Full Text] [Related]
55. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.
Thorpe M; Montalvão A; Pierdomenico F; Moita F; Almeida A
Leuk Res; 2012 Aug; 36(8):1071-3. PubMed ID: 22607959
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine.
Wajid M A; Gupta AK; Das G; Sahoo D; Meena JP; Seth R
Pediatr Hematol Oncol; 2020 Oct; 37(7):573-581. PubMed ID: 32459546
[TBL] [Abstract][Full Text] [Related]
57. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
[TBL] [Abstract][Full Text] [Related]
58. [The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies].
Fan LY; Hu SY; Xiao PF; Lu J; Li J; Yao YH; Ling J; Kong LJ; Liu H; Bian XN
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):679-682. PubMed ID: 30180454
[TBL] [Abstract][Full Text] [Related]
59. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
Goodyear OC; Dennis M; Jilani NY; Loke J; Siddique S; Ryan G; Nunnick J; Khanum R; Raghavan M; Cook M; Snowden JA; Griffiths M; Russell N; Yin J; Crawley C; Cook G; Vyas P; Moss P; Malladi R; Craddock CF
Blood; 2012 Apr; 119(14):3361-9. PubMed ID: 22234690
[TBL] [Abstract][Full Text] [Related]
60. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
